According to the findings of the E2F1-autophagy-p53 regulatory axis in tumor stem cell resistance mechanisms in this study, we further explore the feasibility of a triple therapy involving E2F1 inhibitors, autophagy regulators, and MDM2-p53 axis inhibitors as a potential strategy to overcome tumor stem cell resistance. Here, MDM2 is linked to neoplasm.